ArticleJTO clinical and research reports2026
Validation of the Ninth Edition TNM Classification for Thymic Carcinoma After Complete Resection in a High-Volume Center.
Article in JTO clinical and research reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to externally validate the ninth edition TNM staging system for thymic carcinoma (TC) in an independent Chinese cohort. Methods: We retrospectively analyzed 245 patients with TC who underwent complete surgical resection between 2010 and 2023. Tumors were staged according to the eighth and ninth TNM editions. Overall survival (OS) and disease-free survival (DFS) were assessed using Kaplan-Meier analysis. Model performance was evaluated using the concordance index (C-index), Akaike Information Criterion, R Results: Compared with the eighth edition, the ninth edition exhibited improved discrimination for OS, with a higher C-index (0.724 versus 0.701), lower Akaike Information Criterion (565.81 versus 568.34), higher R Conclusions: The ninth TNM edition provides improved prognostic discrimination after complete resection, although differentiation between stages III and IV remains limited. The Masaoka-Koga system offers complementary value in early stage disease, particularly for DFS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.